MarketsMaze Therapeutics’ Chief Medical Officer Sold 100% of His Direct Holdings. Here’s What This Means for Investors.April 5, 2026
MarketsImmunome’s Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You MoreApril 5, 2026